The WEE1 inhibitor (WEE1i) Adavosertib (AZD1775) has demonstrated preclinical efficacy in multiple cancer types, including paediatric solid tumours (Kolb et al., 2020), pancreatic (Hartman et al., 2021), and lung cancers (Richer et al., 2017), both as monotherapy or in combination with the standard of care. The gene discussed is WEE1; the disease is cancer.